ANTI-VAULT THERAPY FOR MULTI-DRUG RESISTANCE TO CHEMOTHERAPY
UCLA Technology Available For Licensing

Vaults are recently discovered large cellular particles made of proteins and unique small RNA. Vaults are present in large quantities in all eukaryotic cells and are thought to mediate transport between the nucleus and the cytoplasm. The size and symmetry of vaults is similar to the transporter of the nuclear pore complex (NPC) with which it is thought to interact. Very recently a high correlation between the overexpression of vaults and multi-drug resistance to chemotherapy has been established.

UCLA researchers propose a method of generally knocking out the vault function thought to be associated with multi-drug resistance by targeting vault RNA with antisense. They have been successful in targeting and destroying the vault RNA in vitro and are currently testing this method in tissue culture cells.

Reference: UCLA Case No. 1995-597

For additional technical details and current licensing
availability, please contact the following UCLA office:

UCLA Office of Intellectual Property
11000 Kinross Avenue, Suite #200
Los Angeles, CA 90095-7231
Tel: 310-794-0558 Fax: 310-794-0638
email: ncd@research.ucla.edu
Lead Inventor: Leonard Rome

UCLA Technologies Available for Licensing
http://www.research.ucla.edu/tech

Copyright © 2000 The Regents of the University of California.

keywords: therapeutics uclancd ucla technologies intellectual property patents technology transfer invention business card